BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 4, 2026
Home » Authors » John Fox

Articles by John Fox

Parasite-activated immunity may be able to suppress arthritis

June 8, 2016
By John Fox
HONG KONG – The findings of a new collaborative study by Chinese and German scientists suggest that activation in mice of a specific type of immune response, known as a Type 2 (Th2) response, using parasitic worm-derived stimuli, could clear the way to the development of new treatments for rheumatoid arthritis (RA).
Read More

Combination may induce necroptosis to treat AML

May 25, 2016
By John Fox
HONG KONG – The in vivo antileukemic efficacy and safety of a novel combination of apoptosis-regulating drugs seen in a recent study by Australian researchers suggests that inhibition of apoptosis and activation of another type of cell death, necroptosis, warrants clinical investigation as a treatment for acute myeloid leukemia (AML).
Read More

Combination may induce necroptosis to treat AML

May 24, 2016
By John Fox
HONG KONG – The in vivo antileukemic efficacy and safety of a novel combination of apoptosis-regulating drugs seen in a recent study by Australian researchers suggests that inhibition of apoptosis and activation of another type of cell death, necroptosis, warrants clinical investigation as a treatment for acute myeloid leukemia (AML).
Read More

Cancer drug stimulates stem cells, wound healing

May 18, 2016
By John Fox
HONG KONG – A new study has demonstrated for the first time that nanomolar concentrations of a candidate cancer compound may also have therapeutic value in the field of stem cell therapy and tissue regeneration, Chinese researchers reported in the May 9, 2016, early online edition of Proceedings of the National Academy of Sciences.
Read More

Cancer drug stimulates stem cells, wound healing

May 17, 2016
By John Fox
HONG KONG – A new study has demonstrated for the first time that nanomolar concentrations of a candidate cancer compound may also have therapeutic value in the field of stem cell therapy and tissue regeneration, Chinese researchers reported in the May 9, 2016, early online edition of Proceedings of the National Academy of Sciences.
Read More

New therapeutic target identified against glioblastoma

May 11, 2016
By John Fox
HONG KONG – A study by Taiwanese researchers has demonstrated that two glycoproteins are highly expressed in glioblastoma multiforme (GBM) cancer stem cells, and they play a key role in the tumorigenicity of the brain cancer. Both represent promising new potential therapeutic targets against the largely incurable disease.
Read More

New therapeutic target identified against glioblastoma

May 9, 2016
By John Fox
HONG KONG – A study by Taiwanese researchers has demonstrated that two glycoproteins are highly expressed in glioblastoma multiforme (GBM) cancer stem cells, and they play a key role in the tumorigenicity of the brain cancer. Both represent promising new potential therapeutic targets against the largely incurable disease.
Read More

Study identifies new therapeutic target for AMD

May 4, 2016
By John Fox
HONG KONG – A recent study by scientists at the Department of Ophthalmology and Visual Sciences of the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) has identified a potential new therapeutic target for age-related macular degeneration (AMD), which is the leading cause of central vision loss in the elderly.
Read More

Study identifies new therapeutic target for AMD

May 4, 2016
By John Fox
HONG KONG – A recent study by scientists at the Department of Ophthalmology and Visual Sciences of the Faculty of Medicine at the Chinese University of Hong Kong (CUHK) has identified a potential new therapeutic target for age-related macular degeneration (AMD), which is the leading cause of central vision loss in the elderly.
Read More

Crystal structure of key Zika viral protein reported

April 27, 2016
By John Fox
HONG KONG — Elucidation of the molecular structure of nonstructural protein 1 (NS1) from the Zika virus by Chinese Academy of Sciences (CAS) researchers shows that NS1 is involved in viral pathogenesis, a finding that could lead to new diagnostic technologies and treatments, including for related pathogens such as dengue and West Nile viruses.
Read More
Previous 1 2 … 45 46 47 48 49 50 51 52 53 … 68 69 Next

Popular Stories

  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • University of Western Australia patents 5-HT2A/B modulators

    BioWorld Science
    University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
  • Neurons

    AA meeting of minds as PTC, Novartis push votoplam in HD

    BioWorld
    What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
  • Nerves within a melanoma tumor

    Innervation can slow, as well as speed, tumor growth, study finds

    BioWorld
    Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
  • Alceptor Therapeutics discovers new α2B-adrenoceptor agonists

    BioWorld Science
    Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing